Supernus Pharmaceuticals Priced, Nasdaq: SUPN
Former Shire sub developing improved drug formulations for epilepsy and ADHD.
Industry: Health Care
First Day Return: +7.4%
Industry: Health Care
SUPN
Former Shire sub developing improved drug formulations for epilepsy and ADHD.
| IPO Data | |
|---|---|
| IPO File Date | 12/23/2010 |
| Offer Price | $5.00 |
| Price Range $5.00 - $5.00 | |
| Offer Shares (mm) | 10.0 |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 04/30/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Rockville, MD, United States |
| Founded | 2005 |
| Employees at IPO | 71 |
| Website www.supernus.com | |
IPO News for Supernus Pharmaceuticals
Supernus Pharmaceuticals (SUPN) Performance
